A detailed history of Hennion & Walsh Asset Management, Inc. transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Hennion & Walsh Asset Management, Inc. holds 66,567 shares of SAGE stock, worth $706,941. This represents 0.07% of its overall portfolio holdings.

Number of Shares
66,567
Previous 61,499 8.24%
Holding current value
$706,941
Previous $1.33 Million 6.38%
% of portfolio
0.07%
Previous 0.08%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 17, 2024

BUY
$18.62 - $26.95 $94,366 - $136,582
5,068 Added 8.24%
66,567 $1.25 Million
Q4 2023

Jan 10, 2024

SELL
$17.1 - $22.26 $410,331 - $534,150
-23,996 Reduced 28.07%
61,499 $1.33 Million
Q3 2023

Oct 27, 2023

BUY
$16.75 - $48.98 $71,388 - $208,752
4,262 Added 5.25%
85,495 $1.76 Million
Q2 2023

Aug 09, 2023

BUY
$40.65 - $59.54 $344,549 - $504,661
8,476 Added 11.65%
81,233 $3.82 Million
Q1 2023

Apr 20, 2023

BUY
$37.27 - $46.57 $64,849 - $81,031
1,740 Added 2.45%
72,757 $3.05 Million
Q4 2022

Jan 12, 2023

SELL
$32.2 - $43.61 $301,810 - $408,756
-9,373 Reduced 11.66%
71,017 $2.71 Million
Q3 2022

Nov 14, 2022

BUY
$32.28 - $43.27 $63,656 - $85,328
1,972 Added 2.51%
80,390 $3.15 Million
Q2 2022

Jul 19, 2022

BUY
$27.52 - $37.99 $436,632 - $602,749
15,866 Added 25.36%
78,418 $2.53 Million
Q1 2022

Apr 26, 2022

BUY
$30.71 - $45.71 $315,207 - $469,167
10,264 Added 19.63%
62,552 $2.07 Million
Q4 2021

Feb 14, 2022

BUY
$37.06 - $47.11 $533,404 - $678,054
14,393 Added 37.98%
52,288 $2.22 Million
Q3 2021

Nov 12, 2021

SELL
$40.26 - $57.37 $33,617 - $47,903
-835 Reduced 2.16%
37,895 $1.68 Million
Q2 2021

Aug 13, 2021

SELL
$54.88 - $79.29 $23,104 - $33,381
-421 Reduced 1.08%
38,730 $2.2 Million
Q1 2021

May 17, 2021

BUY
$70.65 - $96.76 $2.77 Million - $3.79 Million
39,151 New
39,151 $2.93 Million

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $631M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Hennion & Walsh Asset Management, Inc. Portfolio

Follow Hennion & Walsh Asset Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hennion & Walsh Asset Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Hennion & Walsh Asset Management, Inc. with notifications on news.